Positron emission tomography: Brain tumors and lung cancer

Rosalie J Hagge, T. Z. Wong, R. E. Coleman

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

F-18 fluorodeoxyglucose positron emission tomography is a uniquely powerful diagnostic tool that noninvasively provides information that is critical to appropriate clinical management of patients with non-small cell lung cancer. Not only does the functional information provided by PET complement and clarify the anatomic information supplied by CT and MR imaging, but the superior sensitivity and negative predicted value of PET allow for improved accuracy in diagnosis, prognosis, staging, and monitoring the effects of treatment. With better information at their disposal, clinicians and patients are able to make better-informed decisions, contributing to more appropriate amd more cost-effective medical care. Truly, FDG-PET has earned its place as the new standard of care in imaging non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)871-881
Number of pages11
JournalRadiologic Clinics of North America
Volume39
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Brain Neoplasms
Positron-Emission Tomography
Lung Neoplasms
Fluorodeoxyglucose F18
Standard of Care
Health Care Costs
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Positron emission tomography : Brain tumors and lung cancer. / Hagge, Rosalie J; Wong, T. Z.; Coleman, R. E.

In: Radiologic Clinics of North America, Vol. 39, No. 5, 2001, p. 871-881.

Research output: Contribution to journalArticle

Hagge, Rosalie J ; Wong, T. Z. ; Coleman, R. E. / Positron emission tomography : Brain tumors and lung cancer. In: Radiologic Clinics of North America. 2001 ; Vol. 39, No. 5. pp. 871-881.
@article{e1c200f26b7441448add78ba2768ea53,
title = "Positron emission tomography: Brain tumors and lung cancer",
abstract = "F-18 fluorodeoxyglucose positron emission tomography is a uniquely powerful diagnostic tool that noninvasively provides information that is critical to appropriate clinical management of patients with non-small cell lung cancer. Not only does the functional information provided by PET complement and clarify the anatomic information supplied by CT and MR imaging, but the superior sensitivity and negative predicted value of PET allow for improved accuracy in diagnosis, prognosis, staging, and monitoring the effects of treatment. With better information at their disposal, clinicians and patients are able to make better-informed decisions, contributing to more appropriate amd more cost-effective medical care. Truly, FDG-PET has earned its place as the new standard of care in imaging non-small cell lung cancer.",
author = "Hagge, {Rosalie J} and Wong, {T. Z.} and Coleman, {R. E.}",
year = "2001",
doi = "10.1016/S0033-8389(05)70318-3",
language = "English (US)",
volume = "39",
pages = "871--881",
journal = "Radiologic Clinics of North America",
issn = "0033-8389",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Positron emission tomography

T2 - Brain tumors and lung cancer

AU - Hagge, Rosalie J

AU - Wong, T. Z.

AU - Coleman, R. E.

PY - 2001

Y1 - 2001

N2 - F-18 fluorodeoxyglucose positron emission tomography is a uniquely powerful diagnostic tool that noninvasively provides information that is critical to appropriate clinical management of patients with non-small cell lung cancer. Not only does the functional information provided by PET complement and clarify the anatomic information supplied by CT and MR imaging, but the superior sensitivity and negative predicted value of PET allow for improved accuracy in diagnosis, prognosis, staging, and monitoring the effects of treatment. With better information at their disposal, clinicians and patients are able to make better-informed decisions, contributing to more appropriate amd more cost-effective medical care. Truly, FDG-PET has earned its place as the new standard of care in imaging non-small cell lung cancer.

AB - F-18 fluorodeoxyglucose positron emission tomography is a uniquely powerful diagnostic tool that noninvasively provides information that is critical to appropriate clinical management of patients with non-small cell lung cancer. Not only does the functional information provided by PET complement and clarify the anatomic information supplied by CT and MR imaging, but the superior sensitivity and negative predicted value of PET allow for improved accuracy in diagnosis, prognosis, staging, and monitoring the effects of treatment. With better information at their disposal, clinicians and patients are able to make better-informed decisions, contributing to more appropriate amd more cost-effective medical care. Truly, FDG-PET has earned its place as the new standard of care in imaging non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034815251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034815251&partnerID=8YFLogxK

U2 - 10.1016/S0033-8389(05)70318-3

DO - 10.1016/S0033-8389(05)70318-3

M3 - Article

C2 - 11587059

AN - SCOPUS:0034815251

VL - 39

SP - 871

EP - 881

JO - Radiologic Clinics of North America

JF - Radiologic Clinics of North America

SN - 0033-8389

IS - 5

ER -